Back to Search
Start Over
Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics
- Source :
- Immunity, Inflammation and Disease, Vol 9, Iss 3, Pp 624-627 (2021), Immunity, Inflammation and Disease
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Dupilumab is a monoclonal antibody against the IL‐4 receptor alpha which has shown efficacy in T2 high severe asthmatics in phase 3 randomized controlled trials. The purpose of this real‐life study is to demonstrate the real‐life effectiveness of dupilumab in Austrian severe asthma patients. We retrospectively analyzed all patients receiving dupilumab at our severe asthma clinic. Thirteen patients have so far received dupilumab at our center. The primary outcome, asthma control questionnaire 6‐item scale at 2 weeks, improved by 0.57 points (p = .014), which is statistically and clinically significant. Similarly, the asthma control test at 4 weeks improved by 3.91 points (p = .024), also statistically and clinically significant. Improvements in forced expiratory volume in 1 s at 2 weeks were neither statistically, nor clinically significant. Improvements at 4 weeks (+220 ml, p = .041), and 3 months (+229 ml, p = .006), were statistically significant and clinically borderline significant. No severe adverse events or hypereosinophilia were observed. No adverse events led to treatment discontinuation. Most patients (85%) had previously received monoclonal antibody treatment for severe asthma. Previous monoclonal antibody treatment had been discontinued in these patients due to a lack of clinical response. Dupilumab is effective and safe in Austrian real‐life severe asthmatics. It provides a possible treatment strategy for T2 high severe asthmatics who do not qualify for anti‐immunoglobulin E or anti‐IL5/IL5R monoclonal antibody treatments or do not adequately respond to these.<br />This is a real‐life study that shows that dupilumab is effective and safe in Austrian real‐life severe asthmatics. It rapidly improved asthma control. These improvements are comparable to previous randomized controlled trials.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Immunology
Hypereosinophilia
Antibodies, Monoclonal, Humanized
law.invention
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
Asthma control
Internal medicine
medicine
Immunology and Allergy
Humans
Adverse effect
Retrospective Studies
business.industry
RC581-607
Dupilumab
Asthma
Discontinuation
030104 developmental biology
Asthma Control Questionnaire
Austria
Commentary
medicine.symptom
Immunologic diseases. Allergy
business
Asthma Control Test
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 20504527
- Volume :
- 9
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Immunity, Inflammation and Disease
- Accession number :
- edsair.doi.dedup.....5af8f2ce802bd01b94f4ad5ffc698d7b